Page 50 - Bioscience Inc News Today

Recombinant Protein Market Forecast, Trend Analysis & Competition Tracking: Global Market insightsWith a multi-disciplinary approach, Fact.MR elaborates an extensive analysis of the historical, current and future outlook of the global Recombinant protein as well as the factors responsible for such a growth. Our high...

Zacks Investment Research upgraded shares of Yield10 Bioscience (NASDAQ:YTEN – Get Rating) from a sell rating to a hold rating in a report issued on Wednesday, Zacks.com reports. According to Zacks, “Yield10 Bioscience, Inc. is an agricultural bioscience company. It focuses on the development of disruptive technologies for improvement in crop yield to enhance global […]

Cookies Co-founder Berner to host grand opening event on April 8th in Ann Arbor TORONTO, April 6, 2022 /CNW/ – TerrAscend Corp. (“TerrAscend” or the “Company”) (CSE:... #cookies #Gage #GageCannabis

Maxim Group began coverage on shares of Daré Bioscience (NASDAQ:DARE – Get Rating) in a research report report published on Friday, Marketbeat reports. The brokerage issued a buy rating and a $4.00 target price on the biotechnology company’s stock. Other research analysts have also issued reports about the company. HC Wainwright lifted their target price […]

SCOTTSDALE, AZ / ACCESSWIRE / April 5, 2022 / Today CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. announces today that the company is introducing new powerful

Daré Bioscience (NASDAQ:DARE – Get Rating) had its price target boosted by Roth Capital from $11.00 to $17.00 in a research report report published on Friday, The Fly reports. A number of other analysts also recently weighed in on DARE. Zacks Investment Research downgraded Daré Bioscience from a buy rating to a hold rating in […]

Daré Bioscience (NASDAQ:DARE – Get Rating) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.03), Fidelity Earnings reports. During the same quarter in the previous year, the company posted ($0.22) earnings per share. DARE traded up $0.01 during […]

/PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced...

INVO Bioscience (NASDAQ:INVO – Get Rating) will be announcing its earnings results after the market closes on Thursday, March 31st. Analysts expect the company to announce earnings of ($0.24) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link. INVO opened at $2.75 on Tuesday. […]

INVO Bioscience (NASDAQ:INVO – Get Rating) and Haemonetics (NYSE:HAE – Get Rating) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings. Institutional & Insider Ownership 14.8% of INVO Bioscience shares are held […]